Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Role of YES1 amplification in EGFR mutation-positive non-small cell lung cancer: Primary resistance to afatinib in a patient.

Thoracic cancer - 1 Sept 2020

Tao Junyan, Sun Dantong, Hou Helei

Abstract excerpt

Epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) patients benefit from EGFR tyrosine kinase inhibitors (TKIs), while some patients demonstrate a resistance to EGFR-TKIs. In the case reported here, the NSCLC patient harboring an EGFR-sensitive mutation and YES1 amplification was treated with afatinib as first-line therapy, but was found to have progressive disease four...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Afatinib
Share to Aged
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 32744377
DOI: 10.1111/1759-7714.13583
PMCID: PMC7471017

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Role of YES1 amplification in EGFR mutation-positive non-small cell lung cancer: Primary resistance to afatinib in a patient.PMID 32744377Read ↗

YES1 as a potential target to overcome drug resistance in EGFR-deregulated non-small cell lung cancer.Semantic proximity Read ↗

<i>YES1</i> amplification: a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomicsSemantic proximity Read ↗

YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomicsSemantic proximity Read ↗

The activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated<i>EGFR</i>gene contributes to the resistance to afatinib, erlotinib and osimertinib in human lung cancer cellsSemantic proximity Read ↗

Acquisition of cancer stem cell-like properties in non-small cell lung cancer with acquired resistance to afatinib.Semantic proximity Read ↗

Apatinib added when NSCLC patients get slow progression with EGFR-TKI: A prospective, single-arm study.Semantic proximity Read ↗

Durable complete response after afatinib and crizotinib in an advanced non-small cell lung cancer patient with EGFR L861Q mutation and acquired MET amplification: a case report.Semantic proximity Read ↗

Knockdown of lncRNA BLACAT1 reverses the resistance of afatinib to non-small cell lung cancer via modulating STAT3 signallingSemantic proximity Read ↗

Overcoming T790M-driven acquired resistance to EGFR-TKIs in NSCLC with afatinib: a case report.Semantic proximity Read ↗

Exploiting YES1-Driven EGFR Expression Improves the Efficacy of EGFR Inhibitors.Semantic proximity Read ↗

Successful Afatinib Therapy after Resistance to EGFR-TKI in a Patient with Advanced Adenosquamous Cell Lung Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.